Vivos Inc. announced that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA?s Breakthrough Devices Program. The FDA?s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.147 USD | +0.14% | -17.65% | +103.32% |
May. 09 | Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 18 | Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+103.32% | 60.39M | |
-6.98% | 14.42B | |
-42.66% | 2.62B | |
-14.27% | 2.42B | |
-16.80% | 1.38B | |
-.--% | 1.12B | |
+90.26% | 507M | |
+32.34% | 487M | |
+27.01% | 277M | |
+1.88% | 234M |
- Stock Market
- Equities
- RDGL Stock
- News Vivos Inc.
- Vivos Inc. Announces Radiogel(TM) Precision Radionuclide Therapy(TM) Receives FDA Breakthrough Device Designation